← All indications
Cholangitis
Inflammation of the biliary ductal system (BILE DUCTS); intrahepatic, extrahepatic, or both.
Subtype terms (1)
More specific conditions that are subtypes of Cholangitis in the MeSH hierarchy.
- Cholangitis, Sclerosing
49 drugs (24 approved, 25 experimental)
Drugs by status
Approved for this indication (3)
Phase 4 trials (3)
Phase 3 trials (4)
Phase 2 trials (12)
Organizations
Organization Involved with Phase 4 Indications (32)
- Intercept Pharmaceuticals
- University of Roma La Sapienza
- Huazhong University of Science and Technology
- Aarhus University
- Medical University of Graz
- University of London
- Katholieke Universiteit Leuven
- Osaka University
- Sichuan University
- Universidad Complutense de Madrid
- University of Milan
- University of Padova
- University of Southern California
- University of Tehran
- University of Bern
- University of Bologna
- University of Bonn
- EASL - CLIF Consortium
- University of Copenhagen
- Leiden University
- University of Minnesota
- Jiao Tong University
- Isfahan University
- University of Turin
- University of Barcelona
- Universidad Autonoma de Barcelona
- Ludwig Maximilians University
- J. W. Goethe University
- Erasmus University Rotterdam
- National University of Ireland
- +2 more
Organization Involved with Phase 3 Indications (18)
- Takeda
- Gilead Sciences
- CymaBay Therapeutics, Inc.
- Genfit
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Dr. Falk Pharma GmbH
- Maastricht University
- Arizona State University
- Radboud University
- Stanford University
- University of Groningen
- Utrecht University
- Mayo Clinic
- Istituto Clinico Humanitas - Rozzano (MI), Italy
- University of Amsterdam
- Medical University of Vienna
- Karolinska Institute
- Assistance Publique - Hôpitaux de Paris
Organization Involved with Phase 2 Indications (44)
- Celgene
- Shire
- Merck
- Eli Lilly
- Novartis
- Arena Pharmaceuticals
- Biocad
- Biotie Therapies
- EuroPharma, Inc.
- Enanta Pharmaceuticals
- GlaxoSmithKline
- HighTide Biopharma Pty Ltd
- NGM Biopharmaceuticals, Inc
- Tobira Therapeutics, Inc.
- Zydus Discovery DMCC
- Durect
- EA Pharma Co., Ltd.
- Genkyotex Innovation SAS
- Iltoo Pharma
- National Center for Research Resources (NCRR)
- Harvard University
- Gottfried Wilhelm Leibniz Universität Hannover
- Johns Hopkins University
- University of Florida
- University of Miami
- University of Alberta
- University of Birmingham
- Yale University
- Assiut University
- Kangbuk Samsung Hospital
- +14 more
Organization Involved with Phase 1 Indications (20)
- Genentech
- University of Pennsylvania
- University of Arizona
- University of Pittsburgh
- Baylor University
- Emory University
- Northwestern University
- Ohio State University
- Sacramento Pediatric Gastroenterology
- University of Tennessee
- University of California, Davis
- University of California, San Francisco
- University of Colorado, Denver
- Icahn School of Medicine at Mount Sinai
- Nucleus Network Ltd
- Tokyo Metropolitan Komagome Hospital
- Japan Agency for Medical Research and Development
- Stryker
- PSC Partners Seeking a Cure Foundation
- OHARA Pharmaceutical Co., Ltd.
Organization Involved with Other Experimental Indications (6)